

D.M. Haverstick, PhD, DABCC

PEER REVIEWED PUBLICATIONS:

1. A.H. Gold and D.M. Haverstick: Control of glycogen synthase activity in developing rat liver. **Arch. Biochem. Biophys.** 184:441-452, 1977.
2. D.M. Haverstick, D. Dickemper, and A.H. Gold: Cycloheximide inhibition of insulin control of liver glycogen synthase b to a conversion. **Biochem. Biophys. Res. Commun.** 87:177-183, 1979.
3. A.H. Gold, D. Dickemper, and D.M. Haverstick: Insulin sensitivity of liver glycogen synthase b to a conversion. **Molec. Cell. Biochem.** 25:47-59, 1979.
4. D.M. Haverstick and A.H. Gold: Comparative catalytic properties of liver glycogen synthase from adult and newborn rats. **J. Biol. Chem.** 255:1351-1357, 1980.
5. D.M. Haverstick and A.H. Gold: Isolation of a polydisperse high molecular weight glycogen from rat liver. **Anal. Biochem.** 111:137-145, 1981.
6. D.M. Haverstick, V.M. Dixit, G.A. Grant, W.A. Frazier, and S.A. Santoro: Localization of the hemagglutinating activity of platelet thrombospondin to a 140,000 Dalton thermolytic fragment. **Biochemistry** 23:5597-5603, 1984.
7. D.M. Haverstick and A.H. Gold: Some properties of a liver protein that activates glycogen synthase b. **Biochem. Biophys. Res. Commun.** 126:170-177, 1985.
8. V.M. Dixit, D.M. Haverstick, K. O'Rourke, S.W. Hennessy, G.A. Grant, S.A. Santoro, and W.A. Frazier: A monoclonal antibody against human thrombospondin inhibits platelet aggregation. **Proc. Natl. Acad. Sci. USA** 82:3472-3476, 1985.
9. V.M. Dixit, D.M. Haverstick, K. O'Rourke, S.W. Hennessy, T.J. Broekelmann, J.A. McDonald, G.A. Grant, S.A. Santoro, and W.A. Frazier: Inhibition of platelet aggregation by a monoclonal antibody against human fibronectin. **Proc. Natl. Acad. Sci. USA** 82:3844-3848, 1985.
10. D.M. Haverstick, V.M. Dixit, G.A. Grant, W.A. Frazier, and S.A. Santoro: Characterization of the platelet agglutinating activity of thrombospondin. **Biochemistry** 24:3128-3134, 1985.
11. D.D. Roberts, D.M. Haverstick, V.M. Dixit, W.A. Frazier, S. A. Santoro, and V. Ginsburg: The platelet glycoprotein thrombospondin binds specifically to sulfated glycolipids. **J. Biol. Chem.** 260:9405-9411, 1985.
12. D.M. Haverstick, J. F. Cowan, K.M. Yamada, and S.A. Santoro: Inhibition of platelet adhesion to fibronectin, fibrinogen, and von Willebrand factor substrates by a synthetic tetrapeptide derived from the cell binding domain of fibronectin. **Blood** 66:946-952, 1985.
13. V.M. Dixit, D.M. Haverstick, K.M. O'Rourke, S.W. Hennessy, G.A. Grant, S.A. Santoro, and W.A. Frazier: Effects of anti-thrombospondin monoclonal antibodies on the

agglutination of erythrocytes and fixed, activated platelets by purified thrombospondin. **Biochemistry** 24:4270-4275, 1985.

14. D.M. Haverstick and M. Glaser: Visualization of Ca^{2+} -induced phospholipid domains. **Proc. Natl. Acad. Sci. USA** 84:4475-4479, 1987.
15. D.M. Haverstick and M. Glaser: Visualization of domain formation in the inner and outer leaflets of a phospholipid bilayer. **J. Cell Biol.** 106:1885-1892, 1988.
16. D.M. Haverstick and M. Glaser: The influence of proteins on the reorganization of phospholipid bilayers into large domains. **Biophys. J.** 55:677-682, 1989.
17. D.M. Haverstick, A. Rubenstein, and M.J. Bannon: Striatal tachykinin gene expression regulated by interaction of D-1 and D-2 dopamine receptors. **J. Pharmacol. Expt. Ther.** 248:858-862, 1989.
18. D.M. Haverstick and M.J. Bannon: Evidence for dual mechanisms involved in the methamphetamine-induced increases in striatal preprotachykinin mRNA. **J. Biol. Chem.** 264:13140-13144, 1989.
19. D.M. Haverstick, M. Jeziorski, and M.J. Bannon: Developmental profile of striatal preprotachykinin gene expression. **J. Neurochem.** 55:764-768, 1990.
20. J.G. Granneman, D.M. Haverstick, and A. Chaudry: Relationship between $G_{s\alpha}$ messenger ribonucleic acid splice variants and the molecular forms of $G_{s\alpha}$ protein in rat brown adipose tissue. **Endocrinology** 127:1596-1601, 1990.
21. K. Shibata, D.M. Haverstick, and M.J. Bannon: Tachykinin gene expression in rat limbic nuclei: modulation by dopamine antagonists. **J. Pharmacol. Expt. Ther.** 255:388-392, 1990.
22. D.M. Haverstick, V.H. Englehard, and L.S. Gray: Three intracellular signals for cytotoxic T lymphocyte-mediated killing: Independent roles for protein kinase C, Ca^{2+} influx and Ca^{2+} release from internal stores. **J. Immunol.** 146:3306-3313, 1991.
23. M.J. Bannon, M.S. Poesch, D.M. Haverstick, A. Mandal, I.C.-H. Xue, K. Shibata, and L.J. Dragovic: Preprotachykinin gene expression in the human basal ganglia: Characterization of mRNAs and pre-mRNAs produced by alternate RNA splicing. **Mol. Brain Res.** 12:225-231, 1992.
24. D.M. Haverstick, H. Sakai, and L.S. Gray: Lymphocyte adhesion can be regulated by cytoskeleton-associated, PMA-induced capping of surface receptors. **Am. J. Physiol.** 262:C916-C926, 1992.
25. D.M. Haverstick and L.S. Gray: Lymphocyte adhesion mediated by leukocyte function-associated antigen-1: I. Long term augmentation by transient increases in intracellular cAMP. **J. Immunol.** 149:389-396, 1992.
26. D.M. Haverstick and L.S. Gray: Lymphocyte adhesion mediated by leukocyte function-associated antigen-1: II. Interaction between phorbol ester- and cAMP-sensitive pathways. **J. Immunol.** 149:397-402, 1992.

27. D.M. Haverstick and L.S. Gray: Increased intracellular Ca^{2+} induces Ca^{2+} influx via a Ca^{2+} /calmodulin pathway in human T lymphocytes. **Mol. Biol. Cell** 4:173-184, 1993.
28. J.J. Densmore, D.M. Haverstick, G. Szabo, and L.S. Gray: A voltage operable current is involved in activation-induced Ca^{2+} entry in human lymphocytes while I_{CRAC} has no apparent role. **Am. J. Physiol.** 271:C1494-C1503, 1996.
29. D.M. Haverstick, M.E. Dicus, M.S. Resnick, L.S. Gray and J.J. Sando: A role for protein kinase C β 1 in regulation of Ca^{2+} entry in Jurkat T cells. **J. Biol. Chem.** 272:15426-15433, 1997.
30. M.T. Esser, D.M. Haverstick, C.L. Fuller, C.A. Gullo, and V.L. Braciale: Ca^{2+} signaling modulates cytolytic T lymphocyte effector functions. **J. Exp. Med.** 187:1057-1067, 1998.
31. P.L.M. Lynch, J. Savory, and D.M. Haverstick. Urine total protein using the Vitros dry reagent technology: Modification of diluent to resolve positive bias of diluted samples. **Clin. Chem.** 44:674-675, 1998.
32. J.K.S. Rao, P. Letada, D.M. Haverstick, M.M. Herman, J. Savory. Modifications to the *in situ* TUNEL method for detection of apoptosis in paraffin-embedded tissue sections. **Ann. Clin. Lab. Sci.** 28:131-137, 1998.
33. D.M. Haverstick, J.J. Densmore, and L.S. Gray. Calmodulin regulation of Ca^{2+} entry in Jurkat T cells. **Cell Calcium** 23:361-368, 1998.
34. J. C. Williamson, D. F. Volles, P.L. Lynch, P.D. Rogers, and D. M. Haverstick. Stability of cefepime in peritoneal dialysis solution. **Ann Pharmacotherapy** 33:906-909, 1999.
35. D. M. Haverstick, T.N. Heady, T. L. Macdonald, and L.S. Gray. Inhibition of human prostate cancer proliferation *in vitro* and in a mouse model by compounds synthesized to block Ca^{2+} entry. **Cancer Research** 60:1002-1008, 2000.
36. C. D. Salgado, H. L. Flanagan, D. M. Haverstick, and B. M. Farr. Low rate of false-positive results with use of a rapid HIV test. **Inf Control and Hosp Epid** 23:335-337, 2002.
37. G. C. Bullock, D. E. Bruns, and D. M. Haverstick. Hepatitis C genotype determination by melting curve analysis with a single set of fluorescence resonance energy transfer probes. **Clin. Chem.** 48:2147-2154, 2002.
38. L.S. Gray, E. Perez-Reyes, J.C. Gamorra, D. M. Haverstick, M. Shattock, L. McLatchie, J. Harper, G. Brooks, T. N. Heady, and T. L. Macdonald. The role of voltage gated T type Ca^{2+} channel isoforms in mediating "capacitative" Ca^{2+} entry in cancer cells. **Cell Calcium** 36:489-497, 2004.
39. A. H. B. Wu, M. Packer, A. Smith, R. Bijou, D. Fink, J. Mair, L. Wallentin, N. Johnston, C. S. Feldcamp, D. M. Haverstick, C. Ahnardi, A. Grant, N. Despres, B. Bluestein, and F. Ghani. Analytical and clinical evaluation of the Bayer ADVIA Centaur® automated B-Type Natriuretic Peptide assay in patients with heart failure: A multisite study. **Clin. Chem.** 50:867-873, 2004.

40. W. F. McCalmont, T. N. Heady, J. R. Patterson, M. A. Lindenmuth, D. M. Haverstick, L. S. Gray, T. L. Macdonald. Design, Synthesis, and Biological Evaluation of Novel T-Type Calcium Channel Blockers. **Bioorg. Med. Chem. Lett.** 14:3691-3695, 2004.
41. R.F. Louie, M.J. Lau, J. H. Lee, et al. Multicenter Study on the Prevalence of Blood Contamination on Point-of-Care Glucose Meters and recommendations for controlling contamination. **Point of Care** 4:158-163, 2005.
42. D. M. Haverstick, G. C. Bullock, and D. E. Bruns. Genotyping of Hepatitis C virus (HCV) by melting curve analysis: analytical characteristics and performance. **Clin. Chem.** 50:2405-2407, 2005.
43. W. F. McCalmont, J. R. Patterson, M. A. Lindenmuth, T. N. Heady, D. M. Haverstick, L. S. Gray, and T. L. Macdonald. Investigation into the structure-activity relationship of novel concentration dependent, dual action T-type calcium channel agonists/antagonists. **Bioorg. Med. Chemistry** 13:6821-3839, 2005.
44. L.M. Henrich, D.E. Bruns, D.M. Haverstick, V.G. Reynolds, and J.C. Boyd. Indican interference in Bilirubin assays: A classical solution still applies. **Clin. Chem.** 53:359-360, 2007.
45. D.E. Roberts, T.D. Meakem, C.E. Dalton, D.M. Haverstick, and C. Lynch III. Prevalence of Hyperglycemia in a Pre-Surgical Population. **The Internet Journal of Anesthesiology** 12(1), 2007.
46. L.K. Bechtel, D.M. Haverstick, and C.P. Holstege. Verapamil Toxicity Dysregulates the Phosphatidylinositol 3-Kinase Pathway. **Acad. Emerg. Med.** 15:368-374, 2008.
47. D.M. Haverstick, L.B. Brill, M.G. Scott, and D.E. Bruns. Preanalytical variables in measurement of free (Ionozed) Calcium in Lithium Heparin-Containing Blood Collection Tubes. *Clin Chim Acta* (in press: <http://dx.doi.org/10.1016/j.cca.2009.01.026>)

BOOK CHAPTERS:

1. A.H. Gold and D.M. Haverstick: Comparative catalytic properties of liver glycogen synthase isozymes from newborn and adult rats. From American Chemical Society Symposium: Mechanisms of Polysaccharide Polymerization and Depolymerization, J.J.Marshall, ed., Academic Press, Inc., pp 255-263, 1980.
2. M.J. Bannon, D. M. Haverstick, K. Shibata, and M.S. Pooch: Preprotachykinin gene expression in the forebrain: Regulation by dopamine. **Ann. N.Y. Acad. Sci.** 632:31-37, 1991.
3. D.S. Young, E.W. Bermes, D.M. Haverstick. Specimen Collection and Processing. In Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, CA Burtis, ER Ashwood, and DE Bruns, eds. Elsevier, 2006.
4. D.M Haverstick and A. R. Groszbach. Specimen Collection and Processing. In Fundamentals of Molecular Diagnostics, DE Bruns, ER Ashwood, and CA Burtis, eds. Elsevier, 2007.

5. D.S. Young, E.W. Bermes, and D.M. Haverstick. Specimen Collection and Other Preanalytical Variables. In Fundamentals of Clinical Chemistry, CA Burtis, ER Ashwood, and DE Bruns, eds. Elsevier, 2008.

LETTERS AND OTHER PUBLICATIONS:

1. D. M. Haverstick. Critical Value Called – Read Back Obtained. (invited editorial) **Am J. Clin. Path.** 121:790-791, 2004.
2. P. T. Taylor and D. M. Haverstick. Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer). (Correspondence) **J. Nat. Cancer Inst.** 97:151-152, 2005.
3. D.M. Haverstick. Pharmaceutical Toxicology (book review). **Clin. Chem.** 53:372, 2007.